Windtree Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing novel surfactant therapies for respiratory diseases and other potential applications. Its proprietary technology platform includes a synthetic peptide-containing surfactant (KL4 surfactant) that is structurally similar to endogenous pulmonary surfactant and novel drug-delivery technologies being developed to enable noninvasive administration of aerosolized KL4 surfactant. The company's lead development program comprises AEROSURF, a drug/device product that is in Phase IIb clinical trial to treat respiratory distress syndrome in premature infants. It is also developing other aerosolized KL4 surfactant products. Windtree Therapeutics, Inc. has a strategic collaboration with Eleison Pharmaceuticals, Inc. for using its proprietary pulmonary aerosol delivery system to deliver inhaled lipid cisplatin in combination with KL4 surfactant. The company was formerly known as Discovery Laboratories, Inc. and changed its name to Windtree Therapeutics, Inc. in April 2016. Windtree Therapeutics, Inc. was founded in 1992 and is headquartered in Warrington, Pennsylvania.
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Sub-IndustryBiotechnology
SectorMedical
SymbolOTCMKTS:WINT
CUSIP25466840
Phone215-488-9300
Debt
Debt-to-Equity Ratio-0.53
Current Ratio0.13
Quick Ratio0.13
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual Sales$1.48 million
Price / Sales10.44
Cash FlowN/A
Price / CashN/A
Book Value($7.57) per share
Price / Book-0.54
Profitability
EPS (Most Recent Fiscal Year)N/A
Net Income$-18,440,000.00
Net Margins-956.79%
Return on EquityN/A
Return on Assets-339.58%
Miscellaneous
Employees29
Outstanding Shares3,770,000
Windtree Therapeutics (OTCMKTS:WINT) Frequently Asked Questions
What is Windtree Therapeutics' stock symbol?
Windtree Therapeutics trades on the OTCMKTS under the ticker symbol "WINT."
How were Windtree Therapeutics' earnings last quarter?
Windtree Therapeutics Inc (OTCMKTS:WINT) announced its earnings results on Monday, May, 21st. The biotechnology company reported ($1.40) earnings per share for the quarter. The biotechnology company had revenue of $0.20 million for the quarter. View Windtree Therapeutics' Earnings History.
Who are some of Windtree Therapeutics' key competitors?
Some companies that are related to Windtree Therapeutics include BioCardia (BCDA), TRACON Pharmaceuticals (TCON), Proteon Therapeutics (PRTO), BIONDVAX PHARMA/S (BVXV), CytRx (CYTR), Microbot Medical (MBOT), aTyr Pharma (LIFE), Oncobiologics (ONS), Vical (VICL), Vaxart (VXRT), Titan Pharmaceuticals, Inc. common stock (TTNP), Neuralstem (CUR), Genetic Technologies (GENE), Mymetics (MYMX) and Enzon Pharmaceuticals (ENZN).
Who are Windtree Therapeutics' key executives?
Windtree Therapeutics' management team includes the folowing people:
- Mr. Craig E. Fraser, Pres, CEO & Director (Age 53)
- Mr. John A. Tattory, Sr. VP, CFO & Treasurer (Age 52)
- Dr. Steven G. Simonson M.D., M.H.S, Sr. VP & Chief Medical Officer (Age 59)
- Mr. George Cox, VP of Technical Operations and VP of Manufacturing & Supply Chain (Age 66)
- Ms. Mary B. Templeton Esq., Sr. VP, Gen. Counsel & Corp. Sec. (Age 71)
Has Windtree Therapeutics been receiving favorable news coverage?
Media stories about WINT stock have been trending positive recently, according to Accern Sentiment Analysis. The research group scores the sentiment of media coverage by analyzing more than twenty million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Windtree Therapeutics earned a media sentiment score of 0.30 on Accern's scale. They also assigned press coverage about the biotechnology company an impact score of 45.87 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock's share price in the immediate future.
How do I buy shares of Windtree Therapeutics?
Shares of WINT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Windtree Therapeutics' stock price today?
One share of WINT stock can currently be purchased for approximately $4.10.
How big of a company is Windtree Therapeutics?
Windtree Therapeutics has a market capitalization of $15.45 million and generates $1.48 million in revenue each year. Windtree Therapeutics employs 29 workers across the globe.
How can I contact Windtree Therapeutics?
Windtree Therapeutics' mailing address is 2600 KELLY ROAD SUITE 100, WARRINGTON PA, 18976. The biotechnology company can be reached via phone at 215-488-9300 or via email at [email protected]
MarketBeat Community Rating for Windtree Therapeutics (WINT)
MarketBeat's community ratings are surveys of what our community members think about Windtree Therapeutics and other stocks. Vote "Outperform" if you believe WINT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe WINT will underperform the S&P 500 over the long term. You may vote once every thirty days.
